SCHEMBL6000378

SCHEMBL6000378

Clc1ccc(NCc2ccncc2)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
LMNA P02545 2/20 0.61
KDR P35968 5/20 0.55
FLT1 P17948 4/20 0.54
GAA P10253 3/20 0.54
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
PABPC1 P11940 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MAPK1 P28482 2/20 0.51
CHEK1 O14757 1/20 0.51
ROCK2 O75116 1/20 0.51
RPS6KA5 O75582 1/20 0.51
MAP4K4 O95819 1/20 0.51
CHEK2 O96017 1/20 0.51
PIM1 P11309 1/20 0.51
PRKACA P17612 1/20 0.51
RPS6KB1 P23443 1/20 0.51
AKT1 P31749 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11511690 0.81 MEN1 (0.60) MAPTGAAMEN1KMT2AL3MBTL1
SCHEMBL19242049 0.80 KDM4E (0.61) MAPTGAAKDM4EALDH1A1PABPC1
SCHEMBL10557286 0.80 MAPT (0.65) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5999682 0.79 KDR (0.59) MAPTLMNAKDRFLT1KDM4E
SCHEMBL6078208 0.79 MEN1 (0.57) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL11935890 0.79 MEN1 (0.49) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL6000398 0.78 ALDH1A1 (0.49) MAPTLMNAKDRFLT1GAA
SCHEMBL6000282 0.77 ROCK2 (0.60) MAPTKDRFLT1GAAKDM4E
SCHEMBL18768854 0.76 CYP1A2 (0.57) MAPTLMNAGAAMAPK1CHEK1
SCHEMBL19241691 0.76 F2 (0.56) MAPTGAAKDM4EALDH1A1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C MAPT 3337/4885LMNA 4062/4885KDR 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.